\
&
Contact us
\
&
Contact us
Published on | 2 years ago
Programmes EIT New European BauhausThere is 1 attachment connected to this article.
Attachments are only accessible for people with an account on the NCP Flanders website.
Several EIT Community members are offering support to the most innovative ventures that are driving sustainable change for cities, industries, climate, food, wellbeing and overall quality of life to help foster the New European Bauhaus transformation.
More specifically, they target European startups or scaleups developing innovative solutions with delibarate considerations given to:
The 20 best companies will receive support services amounting to 1 million euro. Ventures accepted into the programme will benefit from a 10,000 EUR grant and 40,000 EUR worth of active support in the form of workshops and events designed to address the following areas:
You can find more information here. The terms and conditions can be found in the attachment.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space Climate, Energy, Mobility Agro-Food, Environment
The Clean Industrial Deal is described as "a bold business plan to support the competitiveness and resilience of our industry." It aims to boost production in green industries, with special focus on energy-intensive industries - vital for European material production and decarbonization goals. 6 main elements The Deal presents measures to boost e... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
